STAT5A/B hyperactivation is a common feature of hematopoietic malignancies, with point mutations being primarily reported for STAT5B. Due to its disease-driving role in various forms of myeloid and lymphoid leukemia/lymphomas, it represents a potential therapeutic target [170]. Here, STAT5B is linked to lymphoma.